Gileno dos Santos de Sousa

Mr. Gileno dos Santos de Sousa

Federal University of Rio de Janeiro, Rio de Janeiro, Brazil
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
GFGiulia D. S. Ferretti
Giulia D. S. Ferretti
JQJulia Quarti
Julia Quarti
GSGileno dos Santos de Sousa
Gileno dos Santos de Sousa
LRLuciana Pereira Rangel
Luciana Pereira Rangel
JSJerson Silva
Jerson Silva
P53 is a tumor suppressor protein that is mutated in more than 50% of cancer cases. When mutated, it frequently results in p53 oncogenic gain of function (GOF), resulting in a greater tendency to aggregate in the phase separation and phase transition pathway. GOFs related to p53 aggregation include chemoresistance, which makes therapy even more difficult. The therapies available for the treatment of cancer are still quite limited, so the study of new molecules and therapeutic targets focusing on p53 aggregates is a promising strategy against cancer. In this review, we classify anticancer molecules with antiaggregation properties into four categories: thiol alkylating agents, designed peptides, agents with chaperone-based mechanisms that inhibit p53 aggregation, and miscellaneous compounds with anti-protein aggregation properties that have been studied in neurodegenerative diseases. Furthermore, we highlight autophagy as a possible degradation pathway for aggregated p53. Here, considering cancer as a protein aggregation disease, we review strategies that have been used to disrupt p53 aggregates, leading to cancer regression.

16 May 2026 in Communications Chemistry
Verified
Journal Article
Open access
GAGuilherme C. de Andrade
Guilherme C. de Andrade
APAnder F. Pereira
Ander F. Pereira
PFPaulo H. B. Ferreira
Paulo H. B. Ferreira
KCKaren D. da Cruz
Karen D. da Cruz
GSGileno dos Santos de Sousa
Gileno dos Santos de Sousa
GOGuilherme de Oliveira
Guilherme de Oliveira
Tumor suppressor p53 is uniquely prone to misfolding and aggregation, a property tightly linked to oncogenic mutations and absent in its paralogs, p63 and p73. Yet, the biophysical origins underlying divergent aggregation propensity remain incompletely understood. Here, we integrate fluorescence spectroscopy, high-pressure and chemical denaturation NMR, molecular dynamics simulations, and energetic frustration analysis to dissect the structural and dynamic discrepancies among p53 and its paralogs. Our results reveal that p53 harbors distinct surface-exposed solvation patches and cavity-prone regions promoting local conformational plasticity. Residue-level NMR analysis uncovers a broad, asymmetric distribution of signal intensity changes with pressure, correlating with discrete solvation patches and frustration-prone regions. These features coincide with highly frustrated contact networks and altered hydrophobic core gating, collectively facilitating aggregation-prone states. In contrast, p63 and p73 exhibit more uniform solvation, reduced frustration, and tighter core packing, conferring greater structural stability. These mechanistic differences directly link uneven hydration and compressibility to the heightened amyloid aggregation propensity of p53C. These contrasting energetic landscapes illustrate how evolutionary sequence divergence fine-tunes p53 for functional flexibility at the expense of stability, predisposing it to pathological aggregation. Our findings illuminate the structural determinants that distinguish pathological folding in p53 and may guide therapeutic stabilization strategies.